LAES
SEALSQ Corp
Semiconductors
Market Cap$108M
5Y Perf.-74.6%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
LAES vs XTLB vs NRXP vs SIGA
Revenue, margins, valuation, and 5-year total return — side by side.
XTLB
XTL Biopharmaceuticals Ltd.
Biotechnology
Market Cap$294K
5Y Perf.-45.7%
NRXP
NRx Pharmaceuticals, Inc.
Biotechnology
Market Cap$85M
5Y Perf.-56.3%
SIGA
SIGA Technologies, Inc.
Drug Manufacturers - Specialty & Generic
Market Cap$339M
5Y Perf.-15.7%
LAES vs XTLB vs NRXP vs SIGA — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | LAES | XTLB | NRXP | SIGA |
|---|---|---|---|---|
| Industry | Semiconductors | Biotechnology | Biotechnology | Drug Manufacturers - Specialty & Generic |
| Market Cap | $108M | $294K | $85M | $339M |
| Revenue (TTM) | $35M | $451K | $242K | $94M |
| Net Income (TTM) | $-50M | $-1M | $-38M | $-4.04T |
| Gross Margin | 37.3% | 26.4% | 59.5% | 61.8% |
| Operating Margin | -136.9% | -481.6% | -63.0% | 27.7% |
| Forward P/E | — | — | — | 2.8x |
| Total Debt | $9M | $138K | $631K | $595K |
| Cash & Equiv. | $85M | $371K | $8M | $155M |
LAES vs XTLB vs NRXP vs SIGA — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
LAES
XTLB
NRXP
SIGA
| Stock | May 23 | May 26 | Return |
|---|---|---|---|
| SEALSQ Corp (LAES) | 100 | 25.4 | -74.6% |
| XTL Biopharmaceutic… (XTLB) | 100 | 54.3 | -45.7% |
| NRx Pharmaceuticals… (NRXP) | 100 | 43.7 | -56.3% |
| SIGA Technologies, … (SIGA) | 100 | 84.3 | -15.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: LAES vs XTLB vs NRXP vs SIGA
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: SIGA leads in 3 of 6 categories, making it the strongest pick for capital preservation and lower volatility and dividend income and shareholder returns. NRx Pharmaceuticals, Inc. is the stronger pick specifically for growth and revenue expansion and recent price momentum and sentiment. LAES also leads in specific categories worth noting. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
LAES
SEALSQ Corp
The Quality Compounder
LAES is the clearest fit if your priority is quality.
- -141.3% margin vs SIGA's -43K%
Best for: quality
XTLB
XTL Biopharmaceuticals Ltd.
The Secondary Option
XTLB lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: healthcare exposure
NRXP
NRx Pharmaceuticals, Inc.
The Growth Leader
NRXP is the #2 pick in this set and the best alternative if growth and momentum is your priority.
- 101.1% revenue growth vs XTLB's -173.2%
- +55.3% vs XTLB's -50.9%
Best for: growth and momentum
SIGA
SIGA Technologies, Inc.
The Income Pick
SIGA carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 4 yrs, beta 1.15, yield 12.7%
- Rev growth -31.8%, EPS growth -60.2%, 3Y rev CAGR -5.1%
- 7.6% 10Y total return vs LAES's -71.9%
- Lower volatility, beta 1.15, Low D/E 0.3%, current ratio 11.83x
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | NRXP | 101.1% revenue growth vs XTLB's -173.2% |
| Quality / Margins | LAES | -141.3% margin vs SIGA's -43K% |
| Stability / Safety | SIGA | Beta 1.15 vs LAES's 3.10, lower leverage |
| Dividends | SIGA | 12.7% yield; 4-year raise streak; the other 3 pay no meaningful dividend |
| Momentum (1Y) | NRXP | +55.3% vs XTLB's -50.9% |
| Efficiency (ROA) | SIGA | -7.4% ROA vs NRXP's -489.9% |
LAES vs XTLB vs NRXP vs SIGA — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2024
Segment breakdown not available.
FY 2025
FY 2025
LAES vs XTLB vs NRXP vs SIGA — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLSIGALAGGINGNRXP
Who Leads Where
SIGA leads in 2 of 6 categories
XTLB leads 1 • LAES leads 0 • NRXP leads 0 • 2 tied
Explore the data ↓NRXPNRx Pharmaceuticals, …
0leads
LAESSEALSQ Corp
0leads
XTLBXTL Biopharmaceutical…
1leads
SIGASIGA Technologies, In…
2leads
6 Total Categories
CATEGORYLEADERvs XTLBvs LAESMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
Tied
—
Valuation MetricsMultiples, price ratios, and targets
XTLB2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
SIGA7/9
Total Returns1Y, 3Y, 5Y total returns with dividends
SIGA4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
Evenly matched — LAES and SIGA each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
SIGA is the larger business by revenue, generating $94M annually — 387.5x NRXP's $242,000. LAES is the more profitable business, keeping -141.3% of every revenue dollar as net income compared to SIGA's -43117.4%. On growth, LAES holds the edge at +3.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | LAESSEALSQ Corp | XTLBXTL Biopharmaceut… | NRXPNRx Pharmaceutica… | SIGASIGA Technologies… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $35M | $451,000 | $242,000 | $94M |
| EBITDAEarnings before interest/tax | -$47M | -$1M | -$31M | $26M |
| Net IncomeAfter-tax profit | -$50M | -$1M | -$38M | -$4.04T |
| Free Cash FlowCash after capex | -$31M | $0 | -$12M | $33M |
| Gross MarginGross profit ÷ Revenue | +37.3% | +26.4% | +59.5% | +61.8% |
| Operating MarginEBIT ÷ Revenue | -136.9% | -4.8% | -63.0% | +27.7% |
| Net MarginNet income ÷ Revenue | -141.3% | -2.3% | -157.3% | -43117.4% |
| FCF MarginFCF ÷ Revenue | -88.9% | -3.7% | -49.0% | +35.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | +3.1% | — | — | -11.3% |
| EPS Growth (YoY)Latest quarter vs prior year | +75.0% | +20.0% | -80.0% | — |
Evenly matched — LAES and SIGA each lead in 3 of 6 comparable metrics.
Valuation Metrics
XTLB leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | LAESSEALSQ Corp | XTLBXTL Biopharmaceut… | NRXPNRx Pharmaceutica… | SIGASIGA Technologies… |
|---|---|---|---|---|
| Market CapShares × price | $108M | $293,767 | $85M | $339M |
| Enterprise ValueMkt cap + debt − cash | $32M | $60,767 | $78M | $185M |
| Trailing P/EPrice ÷ TTM EPS | -4.49x | -0.28x | -2.28x | 14.33x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | 2.78x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | — | 7.60x |
| Price / SalesMarket cap ÷ Revenue | 9.79x | 0.65x | 69.15x | 3.58x |
| Price / BookPrice ÷ Book value/share | 1.38x | 0.05x | — | 1.70x |
| Price / FCFMarket cap ÷ FCF | — | — | — | 6.96x |
XTLB leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
SIGA leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
SIGA delivers a -10.7% return on equity — every $100 of shareholder capital generates $-11 in annual profit, vs $-42 for LAES. SIGA carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to LAES's 0.11x. On the Piotroski fundamental quality scale (0–9), NRXP scores 5/9 vs XTLB's 3/9, reflecting solid financial health.
| Metric | LAESSEALSQ Corp | XTLBXTL Biopharmaceut… | NRXPNRx Pharmaceutica… | SIGASIGA Technologies… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -42.3% | -25.5% | — | -10.7% |
| ROA (TTM)Return on assets | -35.2% | -17.7% | -4.9% | -7.4% |
| ROICReturn on invested capital | -165.0% | -54.1% | — | +33.7% |
| ROCEReturn on capital employed | -34.0% | -50.7% | — | +11.3% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 3 | 5 | 5 |
| Debt / EquityFinancial leverage | 0.11x | 0.03x | — | 0.00x |
| Net DebtTotal debt minus cash | -$76M | -$233,000 | -$7M | -$154M |
| Cash & Equiv.Liquid assets | $85M | $371,000 | $8M | $155M |
| Total DebtShort + long-term debt | $9M | $138,000 | $631,000 | $595,169 |
| Interest CoverageEBIT ÷ Interest expense | -13.04x | -13.31x | -24.18x | — |
SIGA leads this category, winning 7 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
SIGA leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in SIGA five years ago would be worth $10,136 today (with dividends reinvested), compared to $92 for NRXP. Over the past 12 months, NRXP leads with a +55.3% total return vs XTLB's -50.9%. The 3-year compound annual growth rate (CAGR) favors SIGA at 6.9% vs LAES's -34.5% — a key indicator of consistent wealth creation.
| Metric | LAESSEALSQ Corp | XTLBXTL Biopharmaceut… | NRXPNRx Pharmaceutica… | SIGASIGA Technologies… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -28.1% | +11.3% | +16.8% | -15.0% |
| 1-Year ReturnPast 12 months | +30.3% | -50.9% | +55.3% | +1.5% |
| 3-Year ReturnCumulative with dividends | -71.9% | -45.7% | -50.6% | +22.2% |
| 5-Year ReturnCumulative with dividends | -71.9% | -80.4% | -99.1% | +1.4% |
| 10-Year ReturnCumulative with dividends | -71.9% | -87.3% | -96.8% | +764.0% |
| CAGR (3Y)Annualised 3-year return | -34.5% | -18.4% | -21.0% | +6.9% |
SIGA leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — NRXP and SIGA each lead in 1 of 2 comparable metrics.
Risk & Volatility
SIGA is the less volatile stock with a 1.15 beta — it tends to amplify market swings less than LAES's 3.10 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NRXP currently trades 79.7% from its 52-week high vs XTLB's 26.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | LAESSEALSQ Corp | XTLBXTL Biopharmaceut… | NRXPNRx Pharmaceutica… | SIGASIGA Technologies… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 3.10x | 1.71x | 1.91x | 1.15x |
| 52-Week HighHighest price in past year | $8.71 | $10.28 | $3.84 | $9.62 |
| 52-Week LowLowest price in past year | $1.99 | $1.05 | $1.62 | $4.29 |
| % of 52W HighCurrent price vs 52-week peak | +35.0% | +26.0% | +79.7% | +49.2% |
| RSI (14)Momentum oscillator 0–100 | 62.0 | 57.0 | 64.7 | 47.0 |
| Avg Volume (50D)Average daily shares traded | 10.4M | 2.4M | 913K | 688K |
Evenly matched — NRXP and SIGA each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: LAES as "Buy", SIGA as "Buy". SIGA is the only dividend payer here at 12.73% yield — a key consideration for income-focused portfolios.
| Metric | LAESSEALSQ Corp | XTLBXTL Biopharmaceut… | NRXPNRx Pharmaceutica… | SIGASIGA Technologies… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | — | — | Buy |
| Price TargetConsensus 12-month target | $7.50 | — | — | — |
| # AnalystsCovering analysts | 2 | — | — | 1 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | +12.7% |
| Dividend StreakConsecutive years of raises | — | — | — | 4 |
| Dividend / ShareAnnual DPS | — | — | — | $0.60 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
SIGA leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). XTLB leads in 1 (Valuation Metrics). 2 tied.
Best OverallSIGA Technologies, Inc. (SIGA)Leads 2 of 6 categories
Loading custom metrics...
LAES vs XTLB vs NRXP vs SIGA: Key Questions Answered
8 questions · data-driven answers · updated daily
01Is LAES or XTLB or NRXP or SIGA a better buy right now?
For growth investors, SIGA Technologies, Inc.
(SIGA) is the stronger pick with -31. 8% revenue growth year-over-year, versus -63. 5% for SEALSQ Corp (LAES). SIGA Technologies, Inc. (SIGA) offers the better valuation at 14. 3x trailing P/E (2. 8x forward), making it the more compelling value choice. Analysts rate SEALSQ Corp (LAES) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — LAES or XTLB or NRXP or SIGA?
Over the past 5 years, SIGA Technologies, Inc.
(SIGA) delivered a total return of +1. 4%, compared to -99. 1% for NRx Pharmaceuticals, Inc. (NRXP). Over 10 years, the gap is even starker: SIGA returned +764. 0% versus NRXP's -96. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — LAES or XTLB or NRXP or SIGA?
By beta (market sensitivity over 5 years), SIGA Technologies, Inc.
(SIGA) is the lower-risk stock at 1. 15β versus SEALSQ Corp's 3. 10β — meaning LAES is approximately 170% more volatile than SIGA relative to the S&P 500. On balance sheet safety, SIGA Technologies, Inc. (SIGA) carries a lower debt/equity ratio of 0% versus 11% for SEALSQ Corp — giving it more financial flexibility in a downturn.
04Which is growing faster — LAES or XTLB or NRXP or SIGA?
By revenue growth (latest reported year), SIGA Technologies, Inc.
(SIGA) is pulling ahead at -31. 8% versus -63. 5% for SEALSQ Corp (LAES). On earnings-per-share growth, the picture is similar: NRx Pharmaceuticals, Inc. grew EPS 43. 9% year-over-year, compared to -223. 8% for SEALSQ Corp. Over a 3-year CAGR, SIGA leads at -5. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — LAES or XTLB or NRXP or SIGA?
SIGA Technologies, Inc.
(SIGA) is the more profitable company, earning 24. 6% net margin versus -23. 4% for NRx Pharmaceuticals, Inc. — meaning it keeps 24. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SIGA leads at 25. 1% versus -1324. 4% for NRXP. At the gross margin level — before operating expenses — SIGA leads at 68. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — LAES or XTLB or NRXP or SIGA?
In this comparison, SIGA (12.
7% yield) pays a dividend. LAES, XTLB, NRXP do not pay a meaningful dividend and should not be held primarily for income.
07Is LAES or XTLB or NRXP or SIGA better for a retirement portfolio?
For long-horizon retirement investors, SIGA Technologies, Inc.
(SIGA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 15), 12. 7% yield, +764. 0% 10Y return). SEALSQ Corp (LAES) carries a higher beta of 3. 10 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SIGA: +764. 0%, LAES: -71. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between LAES and XTLB and NRXP and SIGA?
These companies operate in different sectors (LAES (Technology) and XTLB (Healthcare) and NRXP (Healthcare) and SIGA (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: LAES is a small-cap quality compounder stock; XTLB is a small-cap quality compounder stock; NRXP is a small-cap quality compounder stock; SIGA is a small-cap deep-value stock. SIGA pays a dividend while LAES, XTLB, NRXP do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.